Form 4: Rigel CEO Granted 53,915 Restricted Stock Units

Rigel Pharmaceuticals CEO and President Raul R. Rodriguez was granted 53,915 Restricted Stock Units, vesting quarterly over three years starting March 31, 2026.

Summary

• Raul R. Rodriguez, CEO, President, and Director of Rigel Pharmaceuticals Inc. (RIGL), was granted 53,915 shares of common stock.
• The shares are to be acquired upon the vesting of a Restricted Stock Unit (RSU) award.
• The RSU award vests quarterly over a period of three years.
• The first quarterly vesting is scheduled to occur on March 31, 2026.
• Following this transaction, Raul R. Rodriguez beneficially owns 282,017 shares of common stock.
• The transaction date for the RSU grant was February 17, 2026, with a price of $0 per share, typical for RSU grants.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management's interests with long-term shareholder value, without indicating any significant operational or financial changes.

Positives

• The grant of Restricted Stock Units aligns the interests of the CEO with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• This RSU award serves as a retention mechanism, incentivizing the CEO to remain with the company for the three-year vesting period.

Future Outlook

The vesting schedule for the Restricted Stock Units extends over three years, indicating a long-term compensation structure for the CEO, aligning future executive incentives with company performance.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units (RSUs) is a common form of executive compensation in the biotechnology and pharmaceutical industries, designed to align management incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a standard practice across the pharmaceutical and broader technology sectors, comparable to compensation structures at companies like Gilead Sciences or Amgen, which frequently utilize equity awards to incentivize leadership.
• The three-year vesting schedule is typical for such awards, providing a balance between immediate reward and long-term retention, consistent with industry benchmarks for executive equity grants.

Related Party Transactions

• The grant of 53,915 Restricted Stock Units to CEO and President Raul R. Rodriguez represents an executive compensation transaction between the company and an insider.

Stakeholder Impact

• Shareholders: The RSU grant aligns the CEO's financial interests with the company's long-term stock performance, potentially benefiting shareholders through motivated leadership.
• Employees: This compensation structure for the CEO may set a precedent or reflect the company's overall approach to executive incentives.

Next Steps

• The Restricted Stock Units will vest quarterly over the next three years, with the first vest occurring on March 31, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU grant) and does not provide new information that would fundamentally alter the investment thesis for Rigel Pharmaceuticals. It is a standard disclosure of an insider transaction, not indicative of significant operational changes or market-moving news, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

RIGL, Rigel Pharmaceuticals, Form 4, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Raul R. Rodriguez, CEO